{"type":"trials","record":{"id":41502,"source_id":"clinicaltrials-gov","external_id":"NCT07501052","title":"Study of the SCD411 Prefilled Syringe for Treating Adults With Wet Age-Related Macular Degeneration, Retinal Vein Occlusion, Diabetic Macular Edema, or Diabetic Retinopathy","brief_summary":"This is a single-arm, multicenter study to evaluate clinical usability of a pre-filled syringe containing SCD411 in adult patients with neovascular Wet Age-Related Macular Degeneration (AMD), Retinal Vein Occlusion (RVO), Diabetic Macular Edema (DME), or Diabetic Retinopathy (DR)","overall_status":"Completed","phases":["PHASE2"],"study_type":"INTERVENTIONAL","sponsor":"Sam Chun Dang Pharm. Co. Ltd.","enrollment":33,"countries":["United States"],"start_date":"2026-05-13","completion_date":"2026-06-01","last_update_date":"2026-06-08","source_url":"https://clinicaltrials.gov/study/NCT07501052","editorial_summary":"A registered PHASE2 study indexed because it matched monitored longevity research terms. Registry status: Completed. Registration does not establish safety or effectiveness.","first_seen_at":"2026-09-25T01:25:30.378222+00:00","last_seen_at":"2026-09-25T06:20:47.789+00:00","metadata":{"sex":"ALL","acronym":null,"age_range":"18 Years","comparator":null,"organization":"Sam Chun Dang Pharm. Co. Ltd.","interventions":["SCD411 0.05mL (2mg)"],"registry_source":"ClinicalTrials.gov","outcome_measures":["Percentage of successful task completions for product use tasks (from opening the carton to disposal of the used PFS an…","Percentage of successful completions of safety-related critical tasks — Baseline [Day 1]","Percentage of successful completions of essential tasks — Baseline [Day 1]","Number of ocular adverse events (AEs) in the study eye — Baseline through follow up visit - approximately 7 (+2) days p…","Number of serious adverse events (SAEs) in the study eye — Baseline through follow up visit - approximately 7 (+2) days…","Number of non-ocular SAEs — Baseline through follow up visit - approximately 7 (+2) days post injection"],"design_description":"NA · SINGLE GROUP · TREATMENT · NONE","source_has_results":false},"controlled_terms":["Neovascular (Wet) Age-Related Macular Degeneration","Retinal Vein Occlusion","Diabetic Macular Edema","Diabetic Retinopathy","SCD411 0.05mL (2mg)"],"relevance_confidence":100,"source_quality_score":100,"freshness_score":100,"publication_state":"published","match_explanation":"Title contains controlled term: age-related macular degeneration.","quality_checked_at":"2026-09-25T06:20:59.355028+00:00","duplicate_cluster_key":"id:nct07501052","duplicate_of_id":null,"evidence_snapshot":{"status":"structured","version":1,"duration":"2026-05-13 to 2026-06-01","comparator":null,"confidence":"structured-source","population":"ALL · 18 Years","provenance":{"duration":"start_date and completion_date","comparator":"registry arm fields","population":"registry eligibility fields","intervention":"registry intervention fields","participants":"enrollment","study_design":"study_type and registry design fields","evidence_stage":"phases","reported_outcome":"not available","outcomes_measured":"registry outcome-measure fields"},"generated_at":"2026-09-25T06:20:47.823Z","intervention":["SCD411 0.05mL (2mg)"],"participants":33,"study_design":"NA · SINGLE GROUP · TREATMENT · NONE","subject_scope":"Human clinical study registration","evidence_stage":"PHASE2","safety_context":"Eligibility, adverse-event details, and clinical decisions must be checked in the official registry and with qualified clinicians.","source_support":"Structured registry protocol metadata; no finding-level conclusion is generated.","main_limitation":"This is a study registration. No reusable structured result is available here, so it cannot show whether the intervention worked or was safe.","reported_outcome":null,"outcomes_measured":["Percentage of successful task completions for product use tasks (from opening the carton to disposal of the used PFS an…","Percentage of successful completions of safety-related critical tasks — Baseline [Day 1]","Percentage of successful completions of essential tasks — Baseline [Day 1]","Number of ocular adverse events (AEs) in the study eye — Baseline through follow up visit - approximately 7 (+2) days p…","Number of serious adverse events (SAEs) in the study eye — Baseline through follow up visit - approximately 7 (+2) days…","Number of non-ocular SAEs — Baseline through follow up visit - approximately 7 (+2) days post injection"],"regulatory_context":"Trial registration is not regulatory approval and does not establish that an intervention is available."},"clinical_trial_topics":[{"topic_slug":"vision-aging","is_published":true,"match_reasons":["Title contains controlled term: age-related macular degeneration.","Abstract contains controlled term: age-related macular degeneration.","Source terminology contains: age-related macular degeneration.","Title supplies longevity context: age-related.","Study type is explicitly identified as INTERVENTIONAL."],"matched_fields":["title","abstract","controlled terminology","title context","study type"],"relevance_score":100,"intelligence_topics":{"name":"Vision ageing","slug":"vision-aging"}}],"content_sources":{"name":"ClinicalTrials.gov","homepage_url":"https://clinicaltrials.gov/"}},"canonical_url":"https://www.immortal.life/trials/41502","automation_disclosure":"Generated automatically from cited source metadata. No scientist, clinician, researcher, editor, or human reviewer evaluates this publication before release."}